Rick,
My apologies; I should've known I'd hit a sore spot!
But I really didn't mean to imply the GLIA was a poor pick. I started looking at it because it was in that portfolio and I have around 20,000 shares of it now. Moreover, it's in my personal *real* money portfolio and it's a big enough chunk that I didn't do it on a lark.
I've done as much homework as I'm capable of and I'm convinced that it's a good pick. You can hardly be faulted for timing in this case; no one could foresee the FDA issue. But no one could foresee the issue being resolved so quickly either. Yet it was.
I understand V1's point about GLIA being a ``mixed bag", because it has a medical supplies component and a real biotech component. But I *like* mixed bags. And I like them even more when the ``boring" part of the bag looks like a monster cash cow. I'm convinced that even the Prudential valuation of GLIA is only based on ADCON-L and it's extremely conservative at that. By a factor of 3 in my opinion. And that's *not* counting the other ADCONs and *not* counting Perceptin or anything else that might emerge from that side of the company.
Yup, there'll be some choppiness ahead, but I think GLIA has shown a fair bit of strenght as well.
Incidentally, the second largest component of my real holdings is NBIX and I'd not be at all surprised to see both of them double before Summer rolls around. I haven't even seen the typical short attacks on either one lately. Actually, I saw one or two *attempts*, but they faltered immediately.
For kicks, the other mixed bag I like is NABI. Somehow, I'm attracted to companies that have a nice boring source of income to fund their research. I've been in and out of NABI a couple of times this year, but I don't know if I dare trade it much longer. There're strong indications that major accumulation is taking place and the recent rise was clearly *not* momentum players.
Thanks, Torben |
